PDS Biotechnology Shares Drop 15% After Trial Expansion Into Europe
marketwatch.com
news
2022-05-31 17:15:00

By Chris Wack PDS Biotechnology Corp. shares were down 15% to $4.59 Tuesday after the company reported the acceptance of its clinical trial application from the Medicines and Healthcare products Regulatory Agency in the U.K. to allow expansion of its study of PDS0101 in combination with Merck & Co.'s anti-PD-1 therapy Keytruda to the U.K. The company said the MHRA is among several regulatory agencies that PDS Biotech is seeking approval from to expand the trial into various sites outside of the U.
